logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

ESMO 2019 — Advanced endometrial cancer: lenvatinib+pembrolizumab yields high response rates despite high toxicity

Lenvatinib+pembrolizumab seems to prolong PFS regardless of microsatellite instability.